Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 3 , ISSUE 2 ( July-December, 2013 ) > List of Articles


The Adoptive Transfer of HBsAG-specific Splenocytes from Balb/c Congenic Donors into HBsAg Transgenic Mice is not associated to Histographological Damage

Aracelys Blanco, Heidy Trujillo, Dunia Hernández, Daymir García, Yadira Lobaina, Freya Freyre, Nelson Merino, Jose Suarez

Citation Information : Blanco A, Trujillo H, Hernández D, García D, Lobaina Y, Freyre F, Merino N, Suarez J. The Adoptive Transfer of HBsAG-specific Splenocytes from Balb/c Congenic Donors into HBsAg Transgenic Mice is not associated to Histographological Damage. Euroasian J Hepatogastroenterol 2013; 3 (2):97-102.

DOI: 10.5005/jp-journals-10018-1074

License: CC BY-NC 4.0

Published Online: 01-12-2017

Copyright Statement:  Copyright © 2013; The Author(s).


Background: Hepatitis B virus (HBV) infections remain as a major health problem. It has been estimated that about 370 million people are chronically infected worldwide. Chronic infection also increases the risk of liver diseases such as cirrhosis and hepatocellular carcinoma. Current antiviral therapies fail to control viral replication in the long term. Viral persistence has cellular immunity. The limitations of the current available therapies underline the need for alternative therapies. The development of a HBV therapeutic vaccine still remains as a feasible option of treatment despite several drawbacks. Recently, approaches like adoptive T-cell therapy have been evaluated. Materials and methods: The adoptive transfer was done intraperitoneally using Balb/c mice as donors and HBsAg- IgG response and biochemical parameters was evaluated in transgenic mice sera by ELISA. The histopathological analysis of the main organs was carried out. Results and discussion: In the present work we demonstrated ! cause histopathological damage. The potent immune response transferred was developed in non-Tg Balb/c mice after multiple simultaneous intranasal and subcutaneous immunizations with NASVAC, a novel HBV therapeutic vaccine candidate. The results indicated that the transference of immunity is safe and also capable of transiently reducing the HBsAg concentration in the sera of transgenic mice. These data support the safety of the therapeutic vaccination using NASVAC and also are in line with the usefulness of the T-cell therapy for chronic hepatitis B.

PDF Share
  1. Hilleman MR. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 2001 Feb;19(15-16):1837-1848
  2. Telbivudine in the treatment of chronic hepatitis B. Adv Ther 2009 Feb;26(12):155-169
  3. The maze of treatments for hepatitis B. N Engl J Med 2005 Jun;352(26):2743-2746
  4. Role of the cell-mediated immune response in the pathogenesis of hepatitis B virus infection: possible immune-therapeutic strategies. Acta Biomed Ateneo Parmense 1996;67(3-4):87-93
  5. ^ > CD8 cell response: relevance to the design of a therapeutic vaccine for chronic HBV infection. Mol Immunol 2001 Dec;38(6):467-473
  6. Adoptive T-cell therapy as a therapeutic option for chronic hepatitis B. J Viral Hepat 2007 Nov;14 (Suppl 1): 45-50
  7. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002 Mar;122(3): 614-624
  8. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001 Apr;33(4):963-971
  9. Long-term persistence of hepatitis B surface antigen and antibody induced by DNA-mediated immunization results in liver and kidney lesions in mice. Eur J Immunol 2006 Apr;36(4):875-886
  10. Interferón y Biotecnología 1989;6(3):251-257
  11. Correlación del ADN y  animales transgénicos. Rev Cubana Invest Biomed 2000;19(1): 8-9
  12. The effect of the parenteral route of administration on the immune response to simultaneous nasal and parenteral immunizations using a new HBV therapeutic vaccine candidate. Viral Immunol 2010;23(5):521-529
  13. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 2004 Oct;82(5):539-546
  14. Ongoing murine T1 or T2 immune response to the hepatitis B surface antigen are excluded from the liver that expresses transgene-encoded hepatitis B surface antigen. J Immunol 2000 Apr;164(8):4235-4243.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.